The Latest Cardiac and Vascular News
NAARDEN, Netherlands–(BUSINESS WIRE)–NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases, today announced the publication of a new review article in the European Society of Cardiology (ESC) publication Cardiovascular Research examining cholesteryl ester transfer protein (CETP) inhibition as a potentially high-impact therapeutic target for reducing […]
MALVERN, PA & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Phase 2b trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old, has been accepted for presentation in […]
Front Line Medical Technologies Article for CardiacVascular News Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) as an adjunct for Patients Arriving in Cardiac Arrest to the Emergency Room Out-of-hospital cardiac arrest (OHCA) continues to be overwhelmingly fatal despite improvements in Advanced Cardiovascular Life Support (ACLS) protocols and increasing access […]
Cleerly 2.2.0 includes UX updates and three high-value tools to better evaluate heart disease NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced its latest product release, Cleerly 2.2.0, that includes user experience (UX) refinements and three new high-value tools. These updates come in […]
First of its kind service combines a specialized, multidisciplinary clinical care team with an AI-enabled care management platform for automated medication management, earlier interventions and improved outcomes BOSTON, Feb. 9, 2022 /PRNewswire/ — Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced today the launch of Biofourmis Care, a first of […]
Malmö, Sweden, February 9, 2022 Acarix submits breakthrough designation request with FDA for heart failure diagnosis Acarix expands its portfolio and submits a breakthrough designation request for its innovative technology for heart failure diagnosis with the Food and Drug Administration (FDA) in USA. Heart failure affects more than 6 million people in the USA at […]
Ethics Committee Approval is Final Step Prior to Enrollment of Claritas’ Phase 1 Clinical Study of R-107 SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that the Australian Human Research Ethics […]
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner up to 98% with reductions of up to 81% persisting at 150 days Results to be presented in late breaker at the American […]
Company’s reSept™ ASD Occluder Aims to Evolve Septal Closure with its Novel Metal-Free Frame Design BAAR, Switzerland and SANTA CLARA, Calif., Feb. 8, 2022 /PRNewswire/ — atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced it has received approval for the start […]
TEL AVIV, Israel, Feb. 8, 2022 /PRNewswire/ — MedHub, a privately held medical device company focused on improving and simplifying cardiac care by replacing risky and costly invasive procedures with AI image-based tools, today announced that it has successfully secured $1 million bringing the total sum raised to $4.2 million. The round was led by […]
